RenaudBonnet

Practice Leader Private Equity

(T) + 33.1.56.59.39.14

Renaud Bonnet co-chairs Jones Day's global Private Equity Practice, and his practice areas include venture capital, private equity, M&A, and capital markets. He primarily represents technology and life sciences companies, as well as the private equity and industrial investors that finance them, at every stage of development from entrepreneurial start-ups to multibillion dollar global corporations. He has acted as principal lawyer in a significant number of early to late stage financing rounds, LBO and other M&A transactions, joint ventures, initial public offerings, rights issues, private placements, and tender offers.

Renaud's recent experience includes representations of technology and life sciences companies Adocia, Advicenne, Ansys, Cellectis, Criteo, Devialet, EcoVadis, HRA Pharma, Ivalua, Mauna Kea Technologies, Nanobiotix, Planisware, Prodways, Sigfox, Talend, TxCell, Voltalia, and Voluntis. His recent investor-side representations include: Abingworth, Alven, Bpifrance, Creadev, Danone Ventures, Elaia, Felix Capital, Goldman Sachs, Orange, Hi Inov, Idinvest, Illumina Ventures, Khazana, Seventure, Temasek, and Sofinnova.

Illustrative transactions in which Renaud acted as lead lawyer include: representing the issuer and/or underwriters in more than 100 IPOs and follow-on offerings; the IPOs of Criteo, Cellectis, and Talend on NASDAQ; the tender offers on Completel, Wavecom, Assystem, and TxCell; the LBOs of HRA Pharma by Astorg and Goldman Sachs, Orolia by Eurazeo, A2Mac1 by Five Arrows, and Brico Privé by Florac; the sale of Novexel to AstraZeneca and Synthesio to Ipsos; the acquisition of French technology companies by Autodesk, Criteo, SAP, and Ansys; and the latest financing rounds of Devialet, Ivalua, ManoMano, and Younited.

Renaud is a member of the Consultative Commission on Issuers' Transactions and Financial Information of the French Financial Markets Authority (AMF).

Experience

  • Devialet raises €100 million in funding from group of investorsJones Day represented Devialet SA, a market leader in high end amplifiers, in connection with the €100 million (US$106 million) funding from a group of investors including Ginko Ventures, Foxconn Interconnect Technology, Groupe Renault, Sharp Corporation, Playground Global, Naver, Korelya, Roc Nation, Future French Champions, CM-CIC Investissement, and Bpifrance.
  • Talend completes IPO of American Depositary Shares on NASDAQJones Day represented Talend SA, a software vendor specializing in big data and cloud integration solutions, in connection with its issuance of $94.5 million of American Depositary Shares in an initial public offering on NASDAQ.
  • Goldman Sachs invests in NuxeoJones Day represented Goldman Sachs International in connection with its primary and secondary investment in Nuxeo S.A., a developer of a leading enterprise content management platform which enables organizations to manage complex digital content at massive scale.
  • AccorHotels acquires AvailproJones Day advised AccorHotels, a French multinational hotel group, in connection with its acquisition of Availpro, a leading European software provider to hoteliers.
  • BNP Paribas invests in Fortia Financial SolutionsJones Day represented BNP Paribas Securities Services in connection with its investment in Fortia Financial Solutions, a developer and marketer of financial compliance and risk monitoring solutions.
  • Olfeo completes its owner buyout with Initiative & FinanceJones Day advised Olfeo, a content filtering software vendor, and its managers in connection with its owner buyout with the help of French investment fund, Initiative & Finance.
  • Voltalia completes €170 million share capital increaseJones Day represented Voltalia, an international renewable energy producer, in connection with its €170 million (US$188.6 million) share capital increase through a free allotment of warrants to its shareholders and an international offering to institutional investors inside and outside of France.
  • Bpifrance invests in DoctolibJones Day represented Bpifrance, as lead investor, in connection with a €26 million (US$27.9 million) investment in Doctolib, a developer and marketer of an online booking platform and management software for doctors in Europe.
  • Pharnext completes €30.9 million IPO on Alternext market of Euronext in ParisJones Day represented Pharnext SAS, a biopharmaceutical company that develops new treatments targeting simultaneously several pathological mechanisms in neurological diseases, in connection with the €30.9 million (US$34.4 million) initial public offering on the Alternext market of Euronext in Paris.
  • Cellectis completes $228 million IPOJones Day represented Cellectis SA, a French biotechnology company that develops novel cancer treatments, in connection with its $228 million initial public offering in the United States and Nasdaq listing.
  • Management shareholders complete second owner buyout of Isla Délice groupJones Day acted as counsel to the management shareholders in the second owner buyout of the Isla Délice group, consisting of Amalric SAS and Indev SAS.
  • Trace One sold to HgCapitalJones Day advised Trace One SA, a leading Software as a Service (“SaaS”) platform for the retail and private label goods sectors, in connection with its sale to HgCapital.
  • Orolia sold to EurazeoJones Day advised Orolia S.A., a world leader in reliable GPS-type signals, and its main historical shareholder Mr. Laurent Asscher, in connection with Orolia's leveraged buyout with Eurazeo PME.
  • Laboratoire HRA-Pharma sold to Astorg Partners and Goldman SachsJones Day advised Laboratoire HRA-Pharma SAS, a French pharmaceutical company, and its management in connection with its leveraged buy-out by Astorg Partners and Goldman Sachs.
  • Société Générale, Kempen, and Trout Capital complete €29.9 million private placement of new and secondary shares by DBV TechnologiesJones Day represented Société Générale, Kempen & Co., and Trout Capital in connection with a €29.9 million (US$40.1 million) private placement of new and secondary shares by DBV Technologies, a biotech company specializing in food allergy with innovative products for diagnosis and treatment.
  • HDL Development makes $500 million take-over bid for AssystemJones Day advised HDL Development, a holding company majority owned by Assystem's founding president, in its $500 million take-over bid for Assystem, including the bank financing and guarantee in connection with the bid.
  • Société Générale, CM-CIC Securities, and Canaccord Genuity underwrite €32.4 million IPO by Cellnovo GroupJones Day advised Société Générale Corporate and Investment Banking, CM-CIC Securities, and Canaccord Genuity Limited, as underwriters, in connection with the €32.4 million (US$36.1 million) initial public offering of Common Stock by Cellnovo Group, a medical technology company developing the first connected all-in-one diabetes management system, on the regulated market of Euronext in Paris.
  • Criteo completes IPO of American Depository Shares on NASDAQJones Day advised Criteo S.A., a France-based technology company specializing in performance display advertising, in connection with its issuance of $288 million of Ordinary Shares in an initial public offering in the form of American Depository Shares on NASDAQ.
  • BPI France invests in SarenzaJones Day represented BPI France in connection with a €74 million (US$98.9 million) investment led by BPI France and HLD in Sarenza, a French e-Commerce company specializing in the online sale of shoes and accessories.
  • Mainstay Medical completes IPO in first ever dual listing on regulated market of Euronext in Paris and Enterprise Securities Market of Irish Stock ExchangeJones Day assisted Mainstay Medical Limited, a global medical device company, in connection with its €18.8 million (US$26 million) initial public offering including the first ever dual listing on the regulated market of Euronext in Paris and the Enterprise Securities Market of the Irish Stock Exchange.
  • Speaking Engagements

    • 29 janvier 2014
      Le private equity en 2014 : tendances et opportunités
    • 29 janvier 2013
      Le Private Equity : où en sommes-nous ?
    • 20 septembre 2012
      Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
    • September 20, 2012
      SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
    • 5 avril 2011
      Atelier « Fusions & Acquisitions » de France Biotech - Le point de vue de l'avocat, intervention de Renaud Bonnet
    • 17 juin 2009
      Introductions en bourse : la mission de l’avocat conseil et la problématique règlementaire, Conférence “Penser à votre introduction en bourse : osé ... mais peut-être astucieux ! ” organisée par la Société Générale
    • 3 avril 2007
      Introductions en bourse : feuille de route pratique
    • 18 mai 2006
      Petit déjeuner thématique "Stock options, BCE, actions gratuites"
    • 14 mars 2006
      Cours à l'ESSEC, "Mécanisme d'incitation des managers"
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.